PETNET is the exclusive manufacturer and supplier of Amyvid in the United States
PETNET representatives are available to assist with delivery, contracting, and manufacturing questions.
Amyvid is available for delivery multiple days per week, and over 172,000* doses have been delivered since FDA approval1
*As of May, 20251
CMS=Centers for Medicare & Medicaid Services.
References:
Data on File. Lilly USA, LLC. DOF-AM-US-0002.
Important Safety Information
Risk for Image Misinterpretation and Other Errors
Errors may occur in the estimation of brain amyloid beta neuritic plaque density during Amyvid image interpretation.
The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to an inaccurate assessment. Extensive brain atrophy as well as motion artifacts that distort the image may limit the ability to distinguish gray and white matter on an Amyvid scan.
Perform image interpretation independently of the patient’s clinical information. For cases where there is uncertainty as to the location of cortical signal, use co-registered anatomical imaging to improve localization of signal.
Radiation Risk
Amyvid contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.
The most common adverse reactions reported in clinical trials were headache (1.8%), musculoskeletal pain (0.7%), blood pressure increased (0.7%), nausea (0.7%), fatigue (0.5%), injection site reaction (0.5%), anxiety (0.4%), back pain (0.4%), claustrophobia (0.4%), dizziness (0.4%), feeling cold (0.4%), insomnia (0.4%) and neck pain (0.4%).
Amyvid (florbetapir F 18 injection) for intravenous use is supplied in multidose vials containing 500-1900 MBq/mL.
Amyvid is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline
Selection of patients who are indicated for amyloid beta–directed therapy as described in the prescribing information of the therapeutic products
